Biotech-Focused VHCP Management's Bullish Moves and New Picks
Biotech stocks pop and drop on the smallest whims and whispers, which makes the biotechnology sector one of the most rewarding and volatile sectors out there.
Hedge Fund - VHCP Management
Get Email AlertsAnders Hove And Bong Koh Bio, Returns, AUM, Net Worth
Manager biography is currently missing.
Fund Profile
Filing Period:
| Fund Name: | VHCP Management |
| Manager | Anders Hove And Bong Koh |
| Portfolio Value | $92,999,000 |
| Change This QTR | +0.91% |
Top 13F Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Security | Ticker | Shares | Value | Activity | % Port | History |
|---|---|---|---|---|---|---|---|
| 1. | Dbv Technologies | 456,893 | $31,130,000 | 33.47% | |||
| 2. | HRTX | 1,095,734 | $14,354,000 | 15.43% | |||
| 3. | CHRS | 305,505 | $8,600,000 | 9.24% | |||
| 4. | BCRX | 1,155,104 | $7,312,000 | +15% | 7.86% | ||
| 5. | AVDL | 500,000 | $5,195,000 | 5.58% |
News, Interviews and Investor Letters
Ocera Therapeutics, Inc. (OCRX): Venrock Healthcare Capital Patners Snapping Up Shares
Anders Hove and Bong Koh's VHCP Management disclosed a large increase in its Ocera Therapeutics (OCRX) stake.
Venrock's VHCP Management's Top Picks For 2016
At Insider Monkey, we look at the weighted average returns of the long positions a fund indicates in its 13F filings, in companies with a market cap greater than $1 billion, to estimate the returns of...
Venrock's Latest Pick Shows There Are More Biotech Opportunities to Explore
Biotech is a hot segment right now and even though it has many opportunities, it is also associated with a lot of risks.
VHCP Management Produced Impressive Returns From Its Pharma Stock Picks In The Turbulent Third Quarter
With losses in the high single-digits and volatility hitting the roof, the third quarter of 2015 turned out to be a troublesome period for the equity markets.
Juno Therapeutics Inc (JUNO), Anacor Pharmaceuticals Inc (ANAC): VHCP Management’s Top 3 Biotech Picks
Andres Hove and Bong Koh’s VHCP Management revealed its top 3 biotech picks heading into 2015, in a 13F Form filed with the U.S. Securities and Exchange Commission last month.
Avalanche Biotechnologies Inc (AAVL), Anacor Pharmaceuticals Inc (ANAC), DBV Technologies, Boulogne-Billancourt (DBVT): Among Venrock's Top Succesful Biotech Plays
Venrock Healthcare Capital Partners is a fund that is focused entirely on the healthcare sector, mainly on the biotech sector.
